Compare DGII & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DGII | ZYME |
|---|---|---|
| Founded | 1985 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | N/A | 2017 |
| Metric | DGII | ZYME |
|---|---|---|
| Price | $47.78 | $22.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $48.80 | $32.75 |
| AVG Volume (30 Days) | 336.4K | ★ 594.4K |
| Earning Date | 02-04-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17.55 | N/A |
| EPS | ★ 1.12 | N/A |
| Revenue | ★ $448,817,000.00 | $134,481,000.00 |
| Revenue This Year | $12.80 | $63.10 |
| Revenue Next Year | $5.47 | $93.26 |
| P/E Ratio | $43.08 | ★ N/A |
| Revenue Growth | 6.40 | ★ 116.21 |
| 52 Week Low | $22.39 | $9.03 |
| 52 Week High | $48.33 | $28.49 |
| Indicator | DGII | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 65.02 | 43.91 |
| Support Level | $44.88 | $22.07 |
| Resistance Level | $47.73 | $22.93 |
| Average True Range (ATR) | 2.41 | 0.86 |
| MACD | 0.31 | 0.06 |
| Stochastic Oscillator | 99.26 | 34.62 |
Digi International Inc is a Minnesota corporation that provides business and mission-critical Internet of Things (IoT) connectivity products and services. It operates through two segments: IoT Products & Services, which supports OEMs, enterprise, and government customers in deploying secure IoT connectivity solutions, and IoT Solutions, consisting of SmartSense and its Managed Network-as-a-Service (MNaaS) business offering wireless temperature and condition-based monitoring, employee task management, label printing, and other services. The company generates the majority of its revenue from the IoT Products & Services segment and mainly from the United States, with a presence in Europe, the Middle East and Africa, and the Rest of the world.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.